TFOS Lifestyle: Impact of lifestyle challenges on the ocular surface
- PMID: 37054911
- DOI: 10.1016/j.jtos.2023.04.008
TFOS Lifestyle: Impact of lifestyle challenges on the ocular surface
Erratum in
-
Corrigendum to "TFOS lifestyle: Impact of lifestyle challenges on the ocular surface" [Ocul Surf 28 (2023) 262-303].Ocul Surf. 2024 Apr;32:104. doi: 10.1016/j.jtos.2024.01.010. Epub 2024 Jan 25. Ocul Surf. 2024. PMID: 38280516 No abstract available.
Abstract
Many factors in the domains of mental, physical, and social health have been associated with various ocular surface diseases, with most of the focus centered on aspects of dry eye disease (DED). Regarding mental health factors, several cross-sectional studies have noted associations between depression and anxiety, and medications used to treat these disorders, and DED symptoms. Sleep disorders (both involving quality and quantity of sleep) have also been associated with DED symptoms. Under the domain of physical health, several factors have been linked to meibomian gland abnormalities, including obesity and face mask wear. Cross-sectional studies have also linked chronic pain conditions, specifically migraine, chronic pain syndrome and fibromyalgia, to DED, principally focusing on DED symptoms. A systematic review and meta-analysis reviewed available data and concluded that various chronic pain conditions increased the risk of DED (variably defined), with odds ratios ranging from 1.60 to 2.16. However, heterogeneity was noted, highlighting the need for additional studies examining the impact of chronic pain on DED signs and subtype (evaporative versus aqueous deficient). With respect to societal factors, tobacco use has been most closely linked to tear instability, cocaine to decreased corneal sensitivity, and alcohol to tear film disturbances and DED symptoms.
Keywords: Anxiety; Chronic pain; Depression; Dry eye disease; Mental health; Ocular surface disease; Physical factors; Sleep disorders; Social factors; Systematic review.
Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest Anat Galor: Novartis (C), Novaliq (C), Oyster Point Pharma (C), Palatin Technologies (C), Oculis (C), Dompé (C), Allergan (C), Shire (C) Alexis Ceecee Britten-Jones: Plano (R) Yun Feng: None. Giulio Ferrari: Bausch + Lomb (F) David Goldblum: Roche (F), Novartis (P), Haag-Streit (C), Johnson & Johnson Vision (C) Preeya K. Gupta: Alcon (C), Allergan (C), Aldeyra (C), Azura (C), Expert Opinion (C), HanAll Biopharma (C), Johnson & Johnson Vision (C), Kala (C), New World Medical (C), Novartis (C), Ocular Science (C), Ocular Therapeutix (C), Orasis (C), Oyster Point Pharma (C), Santen (C), Spyglass (C), , Sight Sciences (C), Surface Ophthalmics (C), Sun Pharmaceuticals (C), Tarsus (C), Tear Lab (C), Tear Clear (C), Tissue Tech (C), Visionology (C), Zeiss (C) Jesus Merayo-Lloves: BTI + d(C), Brill(C), Faes Pharma, Sophia(C), Théa (C) Kyung-Sun Na: None. Shehzad A. Naroo: None. Kelly K. Nichols: Azura (F), Tear Science (F), Oyster Point Pharma (I,C), Bausch + Lomb (C), Bruder (C), Dompé (C), HanAll Bio (C), Kala (F,C), Novartis/Shire/Takeda (C), Osmotica (F), Sight Sciences (F), Tear Film Innovations/Alcon/Acquiom (C), Thea (C), Tarsus (C), TopiVert (C), Trukera (C), Versea (C), Xequel (C), Nicox (C), Novaliq (C) Eduardo M. Rocha: Christalia Lab ( Louis Tong: Azura (C), Allergan (C), Santen (C), Alcon/Novartis (F,R), Bausch + Lomb (R), Vivavision Biotech (C) Michael T. M. Wang: None. Jennifer P. Craig: Adelphi Values Ltd (R), Alcon (F,R,C), Asta Supreme (R), Azura Ophthalmics (F,R), E-Swin (F,R), Johnson & Johnson Vision (R), Manuka Health (F), Medmont International (R), Novoxel (R), Oculeve (F), Photon Therapeutics (R), Resono Ophthalmic (F,R), TFOS (S), Th'ea Laboratories (F,R), Topcon (F,R), TRG Natural Pharmaceuticals (F,R).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
